The role of XRCC4 in carcinogenesis and anticancer drug discovery

Recent Patents on Anti-Cancer Drug Discovery

Volumn 3, Issue 3, 2008, Pages 209-219

  Wu, Cheng Nan ^a,b   Liang, Shiu Yun ^a   Tsai, Chia Wen ^a   Bau, Da Tian ^a  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CENTRAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

Cancer; Carcinogenesis; Polymorphism; XRCC4

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN; CARCINOGEN; GENE PRODUCT; MUTANT PROTEIN; PROTEIN SUBUNIT; UNCLASSIFIED DRUG; X RAY CROSS COMPLEMENTING GROUP 4 PROTEIN;

ALLELE; BLADDER CANCER; BREAST CANCER; BREAST CARCINOGENESIS; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CRYSTAL STRUCTURE; DNA DAMAGE; DNA POLYMORPHISM; DNA PROTEIN COMPLEX; DNA REPAIR; DNA STRAND BREAKAGE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG RESEARCH; DRUG TARGETING; ENDOMETRIOSIS; ENVIRONMENTAL FACTOR; EXON; GENE DELETION; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENE SILENCING; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC LINKAGE; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; GLIOMA; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; INTRON; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MOUTH CANCER; MUTATIONAL ANALYSIS; MYELOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; OCCUPATIONAL CANCER; OCCUPATIONAL HAZARD; ONCOGENE; PENETRANCE; PHARMACOGENETICS; POPULATION GENETICS; PREVALENCE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN STRUCTURE; RADIATION HAZARD; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEQUENCE HOMOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; STOICHIOMETRY; STOMACH CANCER; STOMACH CARCINOGENESIS;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DNA REPAIR; DNA-BINDING PROTEINS; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; GENE THERAPY; GENOMICS; HUMANS; NEOPLASMS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 58049208327     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489208786242304     Document Type: Review

References (110)

1. Valerie K, Povirk LF. Regulation and mechanisms of mammalian double-strand break repair. Oncogene 2003; 22: 5792-5812.
2. Pfeiffer P, Goedecke W, Kuhfittig-Kulle S, Obe G. Pathways of DNA double-strand break repair and their impact on the prevention and formation of chromosomal aberrations. Cytogenet Genome Res 2004; 104: 7-13.
3. Bassing CH, Chua KF, Sekiguchi J, et al. Increased ionizing radiation sensitivity and genomic instability in the absence of histone H2AX. Proc Natl Acad Sci USA 2002; 99: 8173-8178.
4. Shrivastav M, De Haro LP, Nickoloff JA. Regulation of DNA double-strand break repair pathway choice. Cell Res 2008; 18: 134-147.
5. Gilley D, Tanaka H, Hande MP, et al. DNA-PKcs is critical for telomere capping. Proc Natl Acad Sci USA 2001; 98: 15084-15088.
6. Goytisolo FA, Samper E, Edmonson S, Taccioli GE, Blasco MA. The absence of the dna-dependent protein kinase catalytic subunit in mice results in anaphase bridges and in increased telomeric fusions with normal telomere length and G-strand overhang. Mol Cell Biol 2001; 21: 3642-3651.
7. Ferguson DO, Alt FW. DNA double strand break repair and chromosomal translocation: lessons from animal models. Oncogene 2001; 20: 5572-5579.
8. Difilippantonio MJ, Zhu J, Chen HT, et al. DNA repair protein Ku80 suppresses chromosomal aberrations and malignant transformation. Nature 2000; 404: 510-514.
9. Gao Y, Ferguson DO, Xie W, et al. Interplay of p53 and DNA-repair protein XRCC4 in tumorigenesis, genomic stability and development. Nature 2000; 404: 897-900.
10. Zhu C, Mills KD, Ferguson DO, et al. Unrepaired DNA breaks in p53-deficient cells lead to oncogenic gene amplification subsequent to translocations. Cell 2002; 109: 811-821.
11. Li Z, Otevrel T, Gao Y, et al. The XRCC4 gene encodes a novel protein involved in DNA double-strand break repair and V(D)J recombination. Cell 1995; 83: 1079-1089.
12. Mari PO, Florea BI, Persengiev SP, et al. Dynamic assembly of end-joining complexes requires interaction between Ku70/80 and XRCC4. Proc Natl Acad Sci USA 2006; 103: 18597-18602.
13. Buck D, Malivert L, de Chasseval R, et al. A novel nonhomologous end-joining factor, is mutated in human immunodeficiency with microcephaly. Cell 2006; 124: 287-299.
14. van Heemst D, Brugmans L, Verkaik NS, van Gent DC. End-joining of blunt DNA double-strand breaks in mammalian fibroblasts is precise and requires DNA-PK and XRCC4. DNA Repair (Amst) 2004; 3: 43-50.
15. Gao Y, Sun Y, Frank KM, et al. A critical role for DNA end-joining proteins in both lymphogenesis and neurogenesis. Cell 1998; 95: 891-902.
16. Weterings E, Chen DJ. The endless tale of non-homologous end-joining. Cell Res 2008; 18: 114-124.
17. Grawunder U, Zimmer D, Kulesza P, Lieber MR. Requirement for an interaction of XRCC4 with DNA ligase IV for wild-type V(D)J recombination and DNA double-strand break repair in vivo. J Biol Chem 1998; 273: 24708-24714.
18. Junop MS, Modesti M, Guarne A, et al. Crystal structure of the Xrcc4 DNA repair protein and implications for end joining. EMBO J 2000; 19: 5962-5970.
19. Sibanda BL, Critchlow SE, Begun J, et al. Crystal structure of an Xrcc4-DNA ligase IV complex. Nat Struct Biol 2001; 8: 1015-1019.
20. Modesti M, Hesse JE, Gellert M. DNA binding of Xrcc4 protein is associated with V(D)J recombination but not with stimulation of DNA ligase IV activity. EMBO J 1999; 18: 2008-2018.
21. Mizuta R, Cheng HL, Gao Y, Alt FW. Molecular genetic characterization of XRCC4 function. Int Immunol 1997; 9: 1607-1613.
22. Dahm K. Role and regulation of human XRCC4-like factor/cernunnos. J Cell Biochem 2008; 104: 1534-1540.
23. Li Y, Chirgadze DY, Bolanos-Garcia VM, et al. Crystal structure of human XLF/Cernunnos reveals unexpected differences from XRCC4 with implications for NHEJ. EMBO J 2008; 27: 290-300.
24. O'Driscoll M, Cerosaletti KM, Girard PM, et al. DNA ligase IV mutations identified in patients exhibiting developmental delay and immunodeficiency. Mol Cell 2001; 8: 1175-1185.
25. Li L, Moshous D, Zhou Y, et al. A founder mutation in Artemis, an SNM1-like protein, causes SCID in Athabascan-speaking Native Americans. J Immunol 2002; 168: 6323-6329.
26. Fu YP, Yu JC, Cheng TC, et al. Breast cancer risk associated with genotypic polymorphism of the nonhomologous end-joining genes: A multigenic study on cancer susceptibility. Cancer Res 2003; 63: 2440-2446.
27. Bau DT, Mau YC, Ding SL, Wu PE, Shen CY. DNA double-strand break repair capacity and risk of breast cancer. Carcinogenesis 2007; 28: 1726-1730.
28. Parkin DE, Davis JA, Symonds RP. Urodynamic findings following radiotherapy for cervical carcinoma. Br J Urol 1988; 61: 213-217.
29. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30.
30. Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970-2002. JAMA 2005; 294: 1255-1259.
31. Black RJ, Bray F, Ferlay J, Parkin DM. Cancer incidence and mortality in the European Union: Cancer registry data and estimates of national incidence for 1990. Eur J Cancer 1997; 33: 1075-1107.
32. Warnakulasuriya S, Sutherland G, Scully C. Tobacco, oral cancer, and treatment of dependence. Oral Oncol 2005; 41: 244-260.
33. Ogden GR. Alcohol and oral cancer. Alcohol 2005; 35: 169-173.
34. Nair U, Bartsch H, Nair J. Alert for an epidemic of oral cancer due to use of the betel quid substitutes gutkha and pan masala: A review of agents and causative mechanisms. Mutagenesis 2004; 19: 251-262.
35. Gupta PC, Ray CS. Smokeless tobacco and health in India and South Asia. Respirology 2003; 8: 419-431.
36. Chiu CF, Tsai MH, Tseng HC, et al. A novel single nucleotide polymorphism in XRCC4 gene is associated with oral cancer susceptibility in Taiwanese patients. Oral Oncol 2008;44:898-902.
37. Tseng HC, Tsai MH, Chiu CF, et al. Association of XRCC4 codon 247 polymorphism with oral cancer susceptibility in Taiwan. Anticancer Res 2008; 28:1687-1691.
38. Department of Health, Taiwan: Cancer registration system annual report. Taiwan, Department of Health.2006.
39. Hopper JL. Genetic epidemiology of female breast cancer. Semin Cancer Biol 2001; 11: 367-374.
40. Singletary SE. Rating the risk factors for breast cancer. Ann Surg 2003; 237: 474-482.
41. Dumitrescu RG, Cotarla I. Understanding breast cancer risk - where do we stand in 2005? J Cell Mol Med 2005; 9: 208-221.
42. Teare MD, Wallace SA, Harris M, Howell A, Birch JM. Cancer experience in the relatives of an unselected series of breast cancer patients. Br J Cancer 1994; 70: 102-111.
43. Nathanson KL, Weber BL. "Other" breast cancer susceptibility genes: Searching for more holy grail. Hum Mol Genet 2001; 10: 715-720.
44. Nathanson KL, Wooster R, Weber BL. Breast cancer genetics: What we know and what we need. Nat Med 2001; 7: 552-556.
45. Bau DT, Fu YP, Chen ST, et al. Breast cancer risk and the DNA double-strand break end-joining capacity of nonhomologous end-joining genes are affected by BRCA1. Cancer Res 2004; 64: 5013-5019.
46. Bau DT, Mau YC, Shen CY. The role of BRCA1 in non-homologous end-joining. Cancer Lett 2006; 240: 1-8.
47. Zhong Q, Boyer TG, Chen PL, Lee WH. Deficient nonhomologous end-joining activity in cell-free extracts from Brca1-null fibroblasts. Cancer Res 2002; 62: 3966-3970.
48. Zhong Q, Chen CF, Chen PL, Lee WH. BRCA1 facilitates microhomology-mediated end joining of DNA double strand breaks. J Biol Chem 2002; 277: 28641-28647.
49. Lee KM, Choi JY, Kang C, et al. Genetic polymorphisms of selected DNA repair genes, estrogen and progesterone receptor status, and breast cancer risk. Clin Cancer Res 2005; 11: 4620-4626.
50. Garcia-Closas M, Egan KM, Newcomb PA, et al. Polymorphisms in DNA double-strand break repair genes and risk of breast cancer: Two population-based studies in USA and Poland, and meta-analyses. Hum Genet 2006; 119: 376-388.
51. Allen-Brady K, Cannon-Albright LA, Neuhausen SL, Camp NJ. A role for XRCC4 in age at diagnosis and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2006; 15: 1306-1310.
52. Chiu CF, Wang HC, Wang CH, et al. A new single nucleotide polymorphism in XRCC4 gene is associated with breast cancer susceptibility in Taiwan. Anticancer Res 2008;267-270.
53. Willems P, Claes K, Baeyens A, et al. Polymorphisms in nonhomologous end-joining genes associated with breast cancer risk and chromosomal radiosensitivity. Genes Chromosomes Cancer 2008; 47: 137-148.
54. Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide. Version 1,0. IARC Cancer Base No. 5. Lyon (France): IARC Press, 2001.
55. Sternberg CN, Calabro F. Chemotherapy and management of bladder tumours. BJU Int 2000; 85: 599-610.
56. IARC Tobacco Smoking. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. IARC Lyon 1985; 38: 244-268.
57. Iscovich J, Castelletto R, Esteve J, et al. Tobacco smoking, occupational exposure and bladder cancer in Argentina. Int J Cancer 1987; 40: 734-740.
58. Zeegers MP, Tan FE, Verhagen AP, Weijenberg MP, van den Brandt PA. Elevated risk of cancer of the urinary tract for alcohol drinkers: A meta-analysis. Cancer Causes Control 1999; 10: 445-451.
59. Sun CL, Yuan JM, Arakawa K, et al. Dietary soy and increased risk of bladder cancer: the Singapore Chinese Health Study. Cancer Epidemiol Biomarkers Prev 2002; 11: 1674-1677.
60. Bruemmer B, White E, Vaughan TL, Cheney CL. Nutrient intake in relation to bladder cancer among middle-aged men and women. Am J Epidemiol 1996; 144: 485-495.
61. Bruemmer B, White E, Vaughan TL, Cheney CL. Fluid intake and the incidence of bladder cancer among middle-aged men and women in a three-county area of western Washington. Nutr Cancer 1997; 29: 163-168.
62. Gago-Dominguez M, Castelao JE, Yuan JM, Yu MC, Ross RK. Use of permanent hair dyes and bladder-cancer risk. Int J Cancer 2001; 91: 575-579.
63. Broberg K, Bjork J, Paulsson K, Hoglund M, Albin M. Constitutional short telomeres are strong genetic susceptibility markers for bladder cancer. Carcinogenesis 2005; 26: 1263-1271.
64. Wu X, Gu J, Grossman HB, et al. Bladder cancer predisposition: A multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet 2006; 78: 464-4679.
65. Wu X, Lin X, Dinney CP, Gu J, Grossman HB. Genetic polymorphism in bladder cancer. Front Biosci 2007; 12: 192-213.
66. Figueroa JD, Malats N, Rothman N, et al. Evaluation of genetic variation in the double-strand break repair pathway and bladder cancer risk. Carcinogenesis 2007; 28: 1788-1793.
67. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
68. Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 1981; 66: 1191-1308.
69. Stein CJ, Colditz GA. Modifiable risk factors for cancer. Br J Cancer 2004; 90: 299-303.
70. Hecht SS, Chen M, Yagi H, Jerina DM, Carmella SG. r-1,t-2,3,c-4-Tetrahydroxy-1,2,3,4-tetrahydrophenanthrene in human urine: A potential biomarker for assessing polycyclic aromatic hydrocarbon metabolic activation. Cancer Epidemiol Biomarkers Prev 2003; 12: 1501-1508.
71. Hukkanen J, Pelkonen O, Hakkola J, Raunio H. Expression and regulation of xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung. Crit Rev Toxicol 2002; 32: 391-411.
72. Neumann AS, Sturgis EM, Wei Q. Nucleotide excision repair as a marker for susceptibility to tobacco-related cancers: a review of molecular epidemiological studies. Mol Carcinog 2005; 42: 65-92.
73. Rudd MF, Webb EL, Matakidou A, et al. Variants in the GH-IGF axis confer susceptibility to lung cancer. Genome Res 2006; 16: 693-701.
74. Ferlay J, Bray F, Sankila R, Parkin DM. Eucan database. Cancer incidence, mortality and prevalence in the European Union (1996 estimates), version 3.1. European Network of Cancer Registries. Lyon: IARC, 2000.
75. Stweard BW. WHO: World Cancer Report 2003 Lyon, France: International Agency for Research on Cancer; 2004.
76. Danesh J. Helicobacter pylori infection and gastric cancer: Systematic review of the epidemiological studies. Aliment Pharmacol Ther 1999; 13: 851-856.
77. Danesh J. Helicobacter pylori and gastric cancer: Time for mega-trials? Br J Cancer 1999; 80: 927-929.
78. World Cancer Research Fund and American Investigation of Cancer Research. Food, nutrition and the prevention of cancer: A global perspective. Menasha, USA: BANTA Book Group, 1997.
79. Tredaniel J, Boffetta P, Buiatti E, Saracci R, Hirsch A. Tobacco smoking and gastric cancer: Review and meta-analysis. Int J Cancer 1997; 72: 565-573.
80. Chiu CF, Wang CH, Wang CL, et al. A novel single nucleotide polymorphism in XRCC4 gene is associated with gastric cancer susceptibility in Taiwan. Ann Surg Oncol 2008; 15: 514-518.
81. Tosi P, Gamberi B, Giuliani N. Biology and treatment of multiple myeloma. Biol Blood Marrow Transplant 2006; 12: 81-86.
82. Kuehl WM, Bergsagel PL. Early genetic events provide the basis for a clinical classification of multiple myeloma. Hematology the Education Program of the American Society of Hematology. Am Soc Hematol 2005; 346-352.
83. Reece DE. An update of the management of multiple myeloma: the changing landscape. Hematology/the Education Program of the American Society of Hematology. Am Soc Hematol 2005; 353-359.
84. Hayden PJ, Tewari P, Morris DW, et al. Variation in DNA repair genes XRCC3, XRCC4, XRCC5 and susceptibility to myeloma. Hum Mol Genet 2007; 16: 3117-3127.
85. Parkin DM, Whelan SL, Feraly J, et al. Cancer incidence in five continents. Lyon: IARC Press, 2002.
86. Kleihues P, Cavenee WK. Pathology and genetics of tumors of the nervous system. Lyon: IARC Press, 2000.
87. Liu Y, Zhang H, Zhou K, et al. Tagging SNPs in nonhomologous end-joining pathway genes and risk of glioma. Carcinogenesis 2007; 28: 1906-1913.
88. Gronberg H. Prostate cancer epidemiology. Lancet 2003; 361: 859-864.
89. Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci 2006; 11: 1388-1413.
90. Department of Health, Taiwan: Cancer registration system annual report. Department of Health, Taiwan, 2006.
91. Chang CH, Chiu CF, Wu HC, et al. Significant association of XRCC4 single nucleotide polymorphisms with prostate cancer susceptibility in Taiwan. Molecular Medicine Reports 2008; 1: 525-530.
92. Falconer H, D'Hooghe T, Fried G. Endometriosis and genetic polymorphisms. Obstet Gynecol Surv 2007; 62: 616-628.
93. Anger DL, Foster WG. The link between environmental toxicant exposure and endometriosis. Front Biosci 2008; 13: 1578-1593.
94. Sagsveen M, Farmer JE, Prentice A, et al. Gonadotrophin-releasing hormone analogues for endometriosis: Bone mineral density. Cochrane Database Syst Rev 2003: CD001297.
95. Yap C, Furness S, Farquhar C. Pre and post operative medical therapy for endometriosis surgery. Cochrane Database Syst Rev 2004: CD003678.
96. Hsieh YY, Bau DT, Chang CC, et al. XRCC4 codon 247*A and XRCC4 promoter -1394*T related genotypes but not XRCC4 intron 3 gene polymorphism are associated with higher susceptibility for endometriosis. Mol Reprod Dev 2008; 75: 946-951.
97. Venter, J.C., Zhang, J.N., Liu, X., Rowe, W., Cravchik, A., Kalush, F., Naik, A., Subramanian, G., Woodage, T. US2007037168 (2007).
98. Evans WE, Relling MV. Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 1999; 286: 487-491.
99. Fagerlund TH, Braaten O. No pain relief from codeine...? An introduction to pharmacogenomics. Acta Anaesthesiol Scand 2001; 45: 140-149.
100. Sargent J. Variations in family composition. Implications for family therapy. Child Adolesc Psychiatr Clin N Am 2001; 10: 577-599.
101. Cortazar P, Johnson BE. Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer. J Clin Oncol 1999; 17: 1625-1631.
102. Nakamura Y, Sekine A, Iida A, et al. Association of single-nucleotide polymorphisms in MTMR9 gene with obesity. Hum Mol Genet 2007; 16: 3017-3026.
103. Yarosh, D.B., Brown, D.A. US2007207195 (2007).
104. Dolan ME, Moschel RC, Pegg AE. Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanein provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci USA 1990; 87: 5368-5372.
105. Dolan ME, Stine L, Mitchell RB, Moschel RC, Pegg AE. Modulation of mammalian O6-alkylguanine-DNA alkyltransferase in vivo by O6-benzylguanine and its effect on the sensitivity of a human glioma tumor to 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea. Cancer Commun 1990; 2: 371-377.
106. Kaina B, Muhlhausen U, Piee-Staffa A, et al. Inhibition of O6-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors: comparison with nonconjugated inhibitors and effect on fotemustine and temozolomide-induced cell death. J Pharmacol Exp Ther 2004; 311: 585-593.
107. Andreassen CN, Alsener J, Overgaard M, Overgaard J. Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes. Radiother Oncol 2003; 69: 127-135.
108. Isla D, Sarries C, Rosell R, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 2004; 15: 1194-1203.
109. Ryu JS, Hong YC, Han HS, et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 2004; 44: 311-316.
110. Takagi M, Futami K, Shimamoto A, et al. Increased chemotherapeutic activity of camptothecin in cancer cells by siRNA-induced silencing of WRN helicase. Biol Pharm Bull 2007; 30: 1958-1961.